Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fitness test could guide safer stem cell transplants for seniors

NCT ID NCT04761770

Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a geriatric assessment—looking at thinking, mobility, mood, nutrition, and medications—can help doctors choose the right transplant intensity for patients aged 60 and older with myeloid blood cancers. The goal is to reduce deaths from transplant complications and improve quality of life. Thirty-three participants will receive a stem cell transplant with a conditioning regimen tailored to their frailty level.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
geriatric assessment and risk-adapted conditioning regimen
What this could lead to
If successful, this approach could help doctors personalize transplant intensity for older patients, potentially reducing deaths from transplant complications and improving quality of life.
What could go wrong
This is a small, early-phase study (33 participants) without a control group, so results may not apply broadly. The geriatric assessment may not reliably predict outcomes, and transplant still carries serious risks like infection and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

33 people

The number who actually took part.

Started

Feb 2021

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * are 60 years or older * have a pathologically confirmed myeloid malignancies including acute myeloid leukemia, ,myelodysplastic syndrome, myeloproliferative neoplasms, or related blood disorders including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, and myelodysplastic/myeloproliferative overlapping syndrome * have \<10% blasts in bone marrow prior to transplant * have a matched related or unrelated donor, mismatched unrelated donor, or haploidentical donor * Meet institutional standard criteria for allogeneic transplantation as determined by the primary transplant physician * Undergoes transplantation using the allocated conditioning regimen intensity defined by the protocol-specified criteria below: * HCT-CI/Age \<5 and IADL normal = myeloablative regimen * HCT-CI/Age ≥5 and/or IADL impairment = RIC/NMA regimen Exclusion Criteria: * Prior hematopoietic cell transplantation * Cord blood donors * Persons with active, refractory disease defined by ≥10% blasts in bone marrow prior to transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative chronic myelomonocytic leukemia hematologic disorder Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative neoplasm Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atypical chronic myeloid leukemia Chronic myelomonocytic leukemia Myelodysplastic syndrome Myelodysplastic/myeloproliferative overlapping syndrome Myeloproliferative neoplasms

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Consent Only)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Consent Only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Consent only)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Consent Only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Consent Only)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Consent Only)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.